Pacific Biosciences of California, Inc. (PACB) Stock
PACB Key Statistics
About Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.
CEO: Mark Van Oene. Company website
PACB — Frequently Asked Questions
What is the PACB stock price today?
Pacific Biosciences of California, Inc. (PACB) trades at $2.09, down 6.70% on the day, as of Nov 12, 2026 09:30 UTC.
What is Pacific Biosciences of California, Inc.'s market cap?
Pacific Biosciences of California, Inc. has a market capitalisation of $649.64M, calculated from the live PACB share price and shares outstanding.
What is the P/E ratio of PACB?
PACB has no meaningful price-to-earnings ratio: Pacific Biosciences of California, Inc. lost $0.42 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Pacific Biosciences of California, Inc. make?
Pacific Biosciences of California, Inc. generated revenue of $161.39M over the trailing twelve months, which puts the stock at 4.03 times sales.
What is the 52-week range for PACB?
PACB has traded between $1.07 and $3.44 over the past 52 weeks, and the last price is 39.2% below that high.
Is Pacific Biosciences of California, Inc. profitable?
No. Pacific Biosciences of California, Inc. is loss-making, with a net margin of -81.31% over the trailing twelve months.
What is the analyst price target for PACB?
Wall Street analysts rate PACB Buy, with an average price target of $1.93, 7.7% below the current price.
What sector is Pacific Biosciences of California, Inc. in?
Pacific Biosciences of California, Inc. is classified under the Healthcare sector and the Medical - Devices industry, and is domiciled in US.
Who is the CEO of Pacific Biosciences of California, Inc.?
Mark Van Oene is the chief executive of Pacific Biosciences of California, Inc., which employs 485 people.
Where can I track PACB in real time?
QFI Terminal shows PACB with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See PACB live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open PACB in Terminal See plans